[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512030":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"CNAO National Center of Oncological Hadrontherapy","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A Survivors",null,"about 80 patients with at least a 5 year follow up with head and neck, skull base and brain tumors and no evidence of progressive disease.",[13],"Other: questionnaires administration",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B","100 patients with histological and\u002For radiological diagnosis of head and neck tumors enrolled at baseline",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"questionnaires administration","Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\\&N43, HADS, Brief COPE, BRCS.\n\nCohort A affected by skull base\u002Fbrain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.\n\nCohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\\&N43.",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Anna Maria Camarda","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+390382078501","camarda@cnao.it",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Cristina Bono","+390382078613","bono@cnao.it",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"CNAO","RECRUITING","Pavia","Pv","27100","Italy","IT",{"type":46,"coordinates":47},"Point",[48,49],9.15917,45.19205,{"lat":49,"lon":48},[52],{"name":53,"role":29,"phone":54,"phoneExt":10,"email":55},"Cristina Bono, MSc","0382078613","cristina.bono@cnao.it",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100512030","hrqol-in-patients-with-solid-tumors-treated-with-hadrontherapy-100512030",false,"NCT05947149","HRQoL in Patients With Solid Tumors Treated With Hadrontherapy","Health Related Quality of Life (HRQoL) in Patients With Solid Tumors Treated With Hadrontherapy (HadroQoL).","HadroQoL","Cohort A (\"survivors\"):\n\nInclusion Criteria\n\n* Patients with at least a follow up of 5 years with head and neck, skull base and brain tumors and no evidence of progressive disease.\n* The patient is able to give consent\n\nExclusion Criteria:\n\n* Re-irradiation.\n* Second tumor.\n* Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life.\n\nCohort B:\n\nInclusion Criteria:\n\n* Histological and\u002For radiological diagnosis of head and neck tumors\n* Patients candidate for curative intent hadrontherapy\n* Patients ≥ 18 years of age\n* The patient is able to give consent\n\nExclusion criteria:\n\n* Re-irradiation.\n* Second tumor\n* Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life\n* Presence of diffused metastasis","ALL","18 Years",{"count":69,"type":70},180,"ESTIMATED","OBSERVATIONAL","The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.",[74,75,76],"Head and Neck Cancer","Skull Base--Cancer","Brain Cancer",[78,79,80],"cancer free survisorship","hadrontherapy","quality of life","2025-08-01",{"date":83,"type":84},"2025-08-06","ACTUAL",{"date":86,"type":84},"2023-03-27",{"date":88,"type":70},"2025-09-26",{"name":5,"class":6},1]